Aviva
BPMC

Aviva’s Blueprint Medicines BPMC Stock Holding History

Aviva’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-8,043
Closed -$861K – 1067
2021
Q4 		$861K Sell
8,043
-9,657
-55% -$1.01M ﹤0.01% 947
2021
Q3 		$1.82M Buy
+17,700
New +$1.65M 0.01% 767
2021
Q2 		– Sell
-12,566
Closed -$1.22M – 878
2021
Q1 		$1.22M Buy
+12,566
New +$1.25M 0.01% 822

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Aviva's BPMC Position: Q1 2022 in Review

Aviva sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 8,043 shares — an estimated $861K sold.

Aviva first reported a position in BPMC in Q1 2021 and held it in 3 quarters. The position peaked at $1.82M in Q3 2021. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

  • Aviva reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
  • Aviva sold 8,043 Blueprint Medicines shares in Q1 2022, an estimated $861K.
  • Aviva first reported a position in Blueprint Medicines in Q1 2021 and held it in 3 quarters.
  • Aviva's Blueprint Medicines position peaked at $1.82M in Q3 2021.
  • 248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Aviva's 13F filing for Q1 2022, filed 13 May 2022.